Enoximone
(Redirected from Perfan)
Enoximone is a phosphodiesterase inhibitor used in the management of heart failure. It is a positive inotrope and vasodilator, which means it increases the force of heart muscle contraction and dilates blood vessels, respectively. Enoximone is typically administered intravenously in a hospital setting.
Mechanism of Action[edit | edit source]
Enoximone works by inhibiting the enzyme phosphodiesterase III (PDE3), which leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP enhances calcium influx into cardiac cells, thereby increasing myocardial contractility. Additionally, increased cAMP in vascular smooth muscle cells causes vasodilation, reducing the workload on the heart.
Clinical Use[edit | edit source]
Enoximone is primarily used in the short-term treatment of severe heart failure, particularly in cases where other treatments have failed or are not suitable. It is often used in acute settings, such as during cardiac surgery or in patients with decompensated heart failure.
Side Effects[edit | edit source]
Common side effects of enoximone include:
- Hypotension (low blood pressure)
- Arrhythmias (irregular heartbeats)
- Thrombocytopenia (low platelet count)
- Headache
- Nausea
Contraindications[edit | edit source]
Enoximone should not be used in patients with:
- Severe aortic stenosis
- Hypertrophic cardiomyopathy
- Known hypersensitivity to enoximone or any of its components
Pharmacokinetics[edit | edit source]
Enoximone is metabolized in the liver and has a half-life of approximately 5 to 10 hours. It is primarily excreted by the kidneys.
History[edit | edit source]
Enoximone was developed in the 1980s and has been used in various countries for the treatment of heart failure. It is marketed under the trade name Perfan.
Research[edit | edit source]
Research into enoximone has focused on its use in acute heart failure and its potential benefits in combination with other heart failure therapies. Studies have examined its effects on hemodynamics and patient outcomes in critical care settings.
Also see[edit | edit source]
| Enoximone Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
